LIPID COMPOSITION AND USE THEREOF FOR DELIVERY OF A THERAPEUTICALLY ACTIVE AGENT TO ENDOTHELIUM
申请人:Pantherna Therapeutics GmbH
公开号:EP3865122A1
公开(公告)日:2021-08-18
The present invention is related to a composition comprising a lipid composition, wherein the lipid composition comprises a cationic lipid, a neutral lipid and a shielding lipid,
wherein the cationic lipid is selected from the group consisting of β-(L-Arginyl)-L-2,3-diamino propionic acid-N-palmityl-N-oleyl-amide, L-Arginyl-β-alanine-N-palmityl-N-oleyl-amide, DOTAP (N-[1-(2,3-Dioleoyloxy)propyl]-N,N,N-trimethylammonium methyl-chloride), DOTMA (1,2-Di-O-octadecenyl-3-trimethylammonium propane (preferably chloride salt)) and DC-cholesterol (3ß-[N-(N',N'-Dimethylaminoethane)-carbamoyl] cholesterol),
wherein the neutral lipid is a zwitterionic phospholipid selected from the group consisting of Diphytanoyl-PE (1,2-Diphytanoyl-sn-glycero-3-phosphoethanolamine), DOPE (1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine), DLPE (1,2-Dilauroyl-sn-glycero-3-phosphoethanolamine), DMPE ((1,2-Dimyristoyl-sn-glycero-3-phosphoethanolamine)), POPE ((1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine)) and DSPE (1,2-Distearoyl-sn-glycero-3 -phosphoethanolamine),
wherein the shielding lipid is a PEGylated lipid selected from the group consisting methoxyPEG-DSPE ((1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)] (ammonium or sodium salt), methoxyPEG-DLG (1,2-Dilauroyl-rac-glycero-3-methoxypolyethylene glycol), methoxyPEG-DMG (1,2-Dimyristoyl-rac-glycero-3-methoxypolyethylene glycol), methoxyPEG-DPG (1,2-Dipalmitoyl-rac-glycero-3-methoxypolyethylene glycol), methoxyPEG-DSG (1,2-Distearoyl-rac-glycero-3-methoxypolyethylene glycol), methoxyPEG-c-DMA (N-[(Methoxy poly(ethylene glycol))carbamyl]-1,2-dimyristyloxlpropyl-3-amine), methoxyPEG-C8-ceramide (N-Octanoyl-sphingosine-1 - succinyl[methoxy(polyethylene glycol)]}), methoxyPEG-C16-ceramide (N-Palmitoyl-sphingosine-1-succinyl[methoxy(polyethylene glycol)]}), and
wherein the composition comprises an mRNA.
本发明涉及一种包含脂质组合物的组合物,其中脂质组合物包含阳离子脂质、中性脂质和屏蔽脂质、
其中阳离子脂质选自以下组成的组 β-(L-精氨酰)-L-2,3-二氨基丙酸-N-棕榈酰-N-油酰-酰胺、L-精氨酰-β-丙氨酸-N-棕榈酰-N-油酰-酰胺、DOTAP(N-[1-(2,3-二油酰氧基)丙基]-N、N,N-三甲基铵甲基氯化物)、DOTMA(1,2-二-O-十八烯基-3-三甲基铵丙烷(最好是氯盐))和 DC-胆固醇(3ß-[N-(N',N'-二甲基氨基乙烷)-氨基甲酰基]胆固醇)、
其中,中性脂质是选自以下组别的齐聚物磷脂:Diphytanoyl-PE(1,2-Diphytanoyl-sn-glycero-3-phosphoethanolamine)、DOPE(1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine)、DLPE(1、2-二月桂酰基-sn-甘油-3-磷脂酰乙醇胺)、DMPE((1,2-二肉豆蔻酰基-sn-甘油-3-磷脂酰乙醇胺))、POPE((1-棕榈酰基-2-油酰基-sn-甘油-3-磷脂酰乙醇胺))和 DSPE(1,2-二硬脂酰基-sn-甘油-3-磷脂酰乙醇胺)、
其中屏蔽脂质是一种 PEG 化脂质,选自由甲氧基 PEG-DSPE (1,2-二硬脂酰-sn-甘油-3-磷脂酰乙醇胺-N-[甲氧基(聚乙二醇)](铵盐或钠盐)组成的组、甲氧基 PEG-DLG(1,2-二月桂酰基-rac-甘油-3-甲氧基聚乙二醇)、甲氧基 PEG-DMG(1,2-二月桂酰基-rac-甘油-3-甲氧基聚乙二醇)、甲氧基 PEG-DPG(1、2-二棕榈酰基-rac-甘油-3-甲氧基聚乙二醇)、甲氧基 PEG-DSG(1,2-二硬脂酰基-rac-甘油-3-甲氧基聚乙二醇)、甲氧基 PEG-c-DMA (N-[(甲氧基聚乙二醇)氨基]-1、2-二肉豆蔻基氧丙基-3-胺)、甲氧基 PEG-C8 角酰胺(N-辛酰基-鞘氨醇-1-琥珀酰基[甲氧基(聚乙二醇)]})、甲氧基 PEG-C16 角酰胺(N-棕榈酰基-鞘氨醇-1-琥珀酰基[甲氧基(聚乙二醇)]}),以及
其中组合物包含 mRNA。